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13 A highly selective nanocarrier for targeted drug transport and delivery to calcium-containing surfaces, 
14 as bone mineral matrix, is described. The nanocarrier, a calcium phosphate (CaP) nanoshell, is capable 
15 of interacting with calcium ions contained in enriched surfaces (Ca2+ modified mica surface, 
16 hydroxyapatite nanoparticles (Ap) films on glass, and Ap modified 45S5® bioactive glass-based 
17 scaffolds) with the consequent disruption of the inorganic structure and release of (bio) molecules 
18 contained in the interior. The antibiotic Levofloxacin (LX) was used as a model drug for the 
19 encapsulation and drug release studies which allowed monitoring by fluorescence spectroscopic 
20 methods. Accumulation and disruption of CaP nanoshells triggered by calcium ions over surfaces, was 
21 followed by microscopy techniques as SEM, AFM, and fluorescence microscopy. Bacterial 
22 susceptibility and time killing assays demonstrated the bactericidal potential of the nanoshells 
23 containing LX. A mechanism for the Ca2+-activated CaP nanoshell accumulation and drug release is 























































































































24 proposed and discussed. 
25
26 KEYWORDS: Calcium phosphate nanoshells; Ca2+activation; surface interaction; carboxyl group; 
27 drug release, bacterial susceptibility.
28
29 1. INTRODUCTION 
30 The development of delivery systems for drugs, proteins, DNA and genes, among others, represents 
31 an accepted and essential strategic tool for the treatment of illness. It addresses issues associated with 
32 pharmaceuticals solubility and stability in the biological environment, maintenance of the drug 
33 effective concentration, enhanced drug performance and acceptability by increasing efficacy, 
34 improving safety and patient compliance.1,2 To meet the requirements of an effective drug delivery, 
35 vehicles are designed to control drug release at a desired target site as response of an internal or external 
36 stimuli. Internal stimuli-responsive nanocarriers release their cargo as a consequence of the specific 
37 physicochemical characteristics of the physiological targeted site as pH, redox and thermal conditions, 
38 and the presence of specific enzymes.3 Nanoparticles of various compositions as calcium phosphate, 
39 gold, bioglass, polymer-modified porous silicon, natural polymers as chitosan and elastine, and 
40 liposomes, are among the drug nanocarriers developed to stimulate mineralization and/or promote 
41 osteoblast activity in bone tissue.4–6 Drug delivery to bone is limited by the tissue characteristics 
42 composed by the nanoscale ensemble of minerals ( 69%) and organic matrix, being hydroxyapatite 
43 the principal component. The local pH diminution and the increase of Ca2+ concentration taking place 
44 during bone resorption were considered as internal boost for drugs release.7 In that sense, the increased 
45 solubility of CaP materials with a pH decrease motivated their use as pH-responsive carriers for drug 
46 delivery.8 























































































































47 Liposomes comprise one of the most effective first generation nanocarriers due to their intrinsic 
48 composition and ability to encapsulate hydrophilic drugs in the aqueous core or hydrophobic molecules 
49 in the lipid bilayer. To overcome their poor mechanical stability and associated burst release, they were 
50 coated with calcium phosphates shells (CaP). 9,10 In fact, calcium phosphate materials have received 
51 much interest in the field of drug delivery due to their excellent biocompatibility and biodegradability 
52 in biological systems, as well as the ability to promote osteoblast adhesion and osteoconductivity, 7,10–
53 13 at the time it provides the nanocarrier of a surface capable of being functionalized for active 
54 targeting.8
55 In the aim of designing a bone responding nanocarrier, we evaluated the response of carboxylic-
56 functionalized calcium phosphate (CaP) coated 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) 
57 liposomes 10 herein denoted CaPLi, towards Ca2+ enriched surfaces. To that purpose, the encapsulation 
58 and delivery of the third generation fluoroquinolonic antibiotic Levofloxacin (LX) was examined. 
59 CaPLi vehicles carrying the antibiotic LX are denoted CaPLiLX. Fig. 1 shows a scheme of the 
60 developed LX-loaded nanocarrier system.
61  
62 Fig. 1. Chemical structure of Levofloxacin (LX) and schematic representation of the nanocarrier. 























































































































63 2. EXPERIMENTAL SECTION
64 2.1 Materials.
65 Lyophilized lipids 1,2-dioleoyl-sn-Glycero-3-Phosphate (DOPA, Avanti Polar Lipids, Alabaster, 
66 Alabama, USA), Levofloxacin (LX, Sigma-Aldrich, St Louis, MO, USA), Acridine orange (AO, 
67 Sigma, St Louis, MO, USA),  Calcium chloride (analytical grade, Anedra), Calcium hydroxide (98.5%, 
68 Sigma Aldrich), Sodium hydroxide (ACS, Cicarelli), Phosphoric acid (85%, Cicarelli), 2-
69 Carboxyethanephosphonic acid (CEPA, 94%, Aldrich), Potassium Chloride (ACS, Biopack),  
70 Potassium Bromide (ACS, J.T. Baker), Sodium chloride (ACS, Anedra),  Potassium phosphate dibasic 
71 (99%, Cicarelli), Chloroform (99.9%, J.T. Baker), Iron chloride (98.3%, J.T. Baker), Ammonium 
72 thiocyanate (97.5%, Cicarelli), Polyvinyl alcohol (PVA, completely hydrolyzed, MW 30000, Merck.), 
73 45S5® and Bioactive glass (BG) commercial powder (particle size 4 µm Na2Ca2Si3O9, SCHOTT Ag, 
74 Standort Landshut) were used as obtained. All solutions were prepared in ultrapure water (0.055 µS 
75 cm−1) obtained from an OSMOION™ purification system.  Regenerated cellulose dialysis membrane 
76 Spectra/Por 1 with a MWCO of 6000-8000 Da was obtained from Spectrum Labs. For scaffolds 
77 preparation fully reticulated polyester-based Polyurethane (PU) foam with 60 ppi (pores per inch) from 
78 Deutschland (Eurofoam GmbH) was used as sacrificial template for the replication method.14 The 
79 foam was cut in cylindrical shape with 12 mm of diameter and 7 mm in thickness. 
80 2.2 Synthesis of Materials.
81 Bioactive glass-ceramic scaffolds (BGS) and hydroxyapatite nanoparticles (Ap) were obtained as 
82 described elsewhere.15 Briefly, scaffolds were prepared by the polyurethane foam method using 
83 commercial 45S5 BG® particles. Hydroxyapatite nanoparticles were obtained by a wet chemical 
84 procedure using H3PO4 and calcium hydroxide as reactants. Surface modification of the scaffold was 
85 performed by deep-coating as described by Dittler et al.15 The modified scaffolds were named Ap-
86 BGS.























































































































87 Calcium phosphate nanoshell synthesis was performed as described in the literature with some 
88 modifications.10 To that purpose, aqueous solutions of DOPA (1 mg/mL) and alternatively LX (100 
89 µM or 6 µM, the latter for fluorescence measurements only) or AO (100 µM) were prepared and 
90 homogenized by vortexing until complete dissolution. The mixture was submitted to 5 cycles of 30 
91 seconds work of tapered probe sonication at 10 W with 30 second rest. Liposome formation after 
92 sonication was suggested by a change in the opalescence of the suspension. 16 The sample was purged 
93 with Ar for 30 minutes in an ice bath and centrifuged at 12000 rpm for 5 minutes. Samples were 
94 labelled as LiLX or LiAO for LX-containing and AO-containing liposomes, respectively.
95 Coating of LiLX and LiAO with CaP and surface derivatized with 2-carboxyethanephosphonic acid to 
96 yield CaP-coated liposomes labeled CaPLiLX and CaPLiAO, respectively, was performed according 
97 to the protocol previously described10 which considered the formation of a Ca2+ deficient calcium 
98 phosphate material. Nanoshells were stored in a dark vessel at 4 °C. Fig. 1 shows the schematic 
99 representation of the nanocarriers synthetized.
100 2.3 Characterization Methods.
101 Nanoshell formation and surface characterization were assessed by Wide Angle X-Ray Scattering 
102 (WAXS), X-Ray Diffraction (XRD), Transmission electron Microscopy (TEM), High Resolution 
103 Scanning Transmission Electron Microscopy (HR-STEM), Energy Dispersive X-ray Spectroscopy 
104 (EDS),    ATR-FTIR spectroscopy, dynamic light scattering (DLS) and electrophoretic mobility (µe), 
105 as described in S.I. “Characterization Methods”. Photoluminescence measurements for CaPLiLX 
106 characterization were performed using a Jobin-Yvon Spex Fluorolog FL3-11 also described in the 
107 supporting information.
108 Lipid quantification of LiLX was accomplished by Stewart colorimetric assay.17 The lipid 
109 concentration on 1:10 diluted LiLX sample measured by Stewart method yielded a concentration of 
110 the order of 0.1 mg/mL, indicating that all the DOPA initially incorporated during synthesis was 
111 forming vesicles.























































































































112 Calcium quantification in CaPLiLX suspension was determined by ICP-OES using a Shimadzu, ICPE-
113 9820 instrument. The quantitative determination was performed according to EPA 6010. 
114 LX encapsulation efficiency (EE%) of LX in the liposomes was determined as the ratio between the 
115 emission intensity upon 330 nm excitation of LX in DOPA mixtures right after vortexing and 
116 sonication (CLXini) and that after liposome dialysis against ultrapure water for 24 h (CLXlipo), EE% = 
117 100CLXlipo/CLXini. The strategy used for the determination of the encapsulation efficiency minimizes 
118 the effects of light scattering and fluorescence quenching due to the presence of liposomes. However, 
119 since no other correction was performed, the obtained EE% is a lower limit value.
120 2.4 Drug release studies.
121 The release profiles of LX were investigated in PBS (pH 7.4) and acetate (pH 4.35) buffers, and in 
122 Simulated body fluid (SBF, pH 7.4) with ion concentrations nearly equal to those of human blood 
123 plasma. A volume of  3 mL CaPLiLX suspension (3.4 x 10-6M LX after dialysis estimated from UV-
124 vis absorption calibration curve, see Section 3.2 below), or alternatively 1.7x10-5M LX solution, were 
125 placed in 2.7 x 4.7 cm dialysis membrane bags and immersed in 200 mL (V0) of PBS or acetate buffers, 
126 or SBF solution. The solutions were incubated at (37 ± 1) ºC under stirring (80 rpm)  up to 75 h. 18 At 
127 different time intervals, 2mL-aliquots (Vi) of the release medium were taken and replaced with the 
128 same volume of fresh media solution. The assays were performed in duplicates. The LX concentration 
129 (Ci) in the aliquots were determined by measuring the fluorescence intensity at 450 nm (PBS buffer 
130 and SBF) or 495 nm (acetate buffer) and the actual LX released concentration obtained by comparison 
131 with a fluorescence-LX concentration calibration curve in the same media. The LX release rate (RR) 
132 was calculated by  where W is the total drug content in the original CaPLiLX samples 𝑅𝑅 = (𝑄𝑛/𝑊)
133 and Qn the cumulative released mass at each time interval n.18 Qn may be calculated as Qn = CnV0+
134 .∑𝑛 ― 1𝑖 = 0 𝐶𝑖 × 𝑉𝑖
135
























































































































137 2.5 Interaction with surfaces.
138 Interaction of LiLX and CaPLiLX samples with Ca2+- rich mica surfaces was addressed by Atomic 
139 Force Microscopy. The measurement was performed in dynamic mode (tapping) thus avoiding 
140 changes induced by lateral forces. In all instances, 10 µl of the samples were dropped on freshly 
141 cleaved mica substrates with and without the previous addition of 10 µL of CaCl2 0.1 M. Samples 
142 were dried under N2 for 10 minutes and analyzed through the use of probes doped with silicon nitride 
143 (Model RTESP, Veeco Instruments, Santa Barbara, CA, USA; tip radii, 8–12 nm, 271–311 kHz, force 
144 constant 40 N m-1). Images were obtained at 25ºC with a Multi-Mode Scanning Probe Microscope 
145 (Veeco) equipped with a Nanoscope V controller (Veeco) at the typical scanning rate (1 Hz).
146 Interaction of CaPLiLX deposited on BGS and Ap-BGS was observed by Scanning Electron 
147 Microscopy (SEM) images taken using an environmental scanning electron microscope FEI Quanta 
148 200, after 10 and 120 minutes of contact. Sample preparation involved fixation and dehydration steps. 
149 Fixation was performed by immersion of the slides in a 2% glutaraldehyde solution at 4ºC for 2 h and 
150 washed with a PBS (pH 7.4) buffer solution. Dehydration was performed by sequential immersion in 
151 cool ethanol-water mixtures (30%, 50%, 70%, 90% and 95%) followed by two immersion processes 
152 in absolute ethanol at room temperature for 20 min. Samples were treated by critical point drying in 
153 order to replace the liquids by CO2 and further metalized with Au.
154 In order to confirm the nanoshell interaction with Ca2+ - enriched surfaces, samples carrying the dye 
155 AO were prepared as described in the experimental section and observed by epifluorescence 
156 microscopy. The samples were deposited over clean glass slides and Ap modified glass slides. 
157 Immediately after deposition (0 min) and after 10 and 180 minutes of contact time, the surfaces were 
158 observed with a fluorescence microscope (Olympus BX51, Olympus Corp., Tokyo, Japan) equipped 
159 with a #WB filter (dichroic mirror DM500, excitation filter BP450-480, emission filter BA515). The 
160 microscope was connected to an Olympus DP71 (Olympus Corp., Tokyo, Japan) color video camera. 























































































































161 Images were taken instantly after opening the microscope shutter to the computer monitor, and in 
162 identical experimental conditions. The images were analyzed by Image J software.
163 2.6 Bacterial studies.
164 Bacterial suspensions. S. aureus ATCC-25923 was inoculated in 150 mL of sterile nutrient broth (NB, 
165 Britania, Argentina) and grown overnight with shaking (170 rpm) at (37 ± 1) ºC. The bacterial 
166 suspension was further adjusted with fresh NB to 1×105 bacteria/ml and used for the biological assays.
167 Antibiotic susceptibility assay. The minimum inhibitory concentration (MIC) of LX against planktonic 
168 S. aureus was performed using the broth microdilution method according to the CLSI guidelines.19 
169 The MIC was defined as the lowest concentration of LX at which bacterial growth was not detected 
170 after 20 h. The minimum bactericidal concentration (MBC) of LX for planktonic bacteria was 
171 determined by plate count method. The antibiotic concentration that produced 99.9% mortality was 
172 considered as the MBC. The assays were performed in triplicates from independent bacterial cultures.
173 In Vitro Time-Kill Experiment. Static time-kill studies were conducted to evaluate the antimicrobial 
174 activity of LX-containing nanoshells according to a previously reported method.20 All experiments 
175 were performed with an initial S. aureus inoculum of ~ 5.0 x 104 bacteria/mL at (37 ± 1) ºC. Time-kill 
176 assays were performed in duplicate using CaPLiLX suspension and LX solution at 2x MIC (MBC, 1.0 
177 μg/mL). At defined time intervals (0, 3, 6, 24 h), bacterial growth was quantified by plating 10-fold 
178 dilutions on nutrient agar (Britania, Argentina). Moreover, growth control was performed and 
179 consisted of a bacterial suspension with fresh NB which was enumerated in the same time interval. 
180 Finally, viable bacteria values were plotted against time for each formulation.
181
182 3. RESULTS AND DISCUSSION 
183 3.1 Characterization of CaPLiLX samples. 























































































































184 HR-STEM, TEM, and SEM electron microscopy images of CaPLiLX samples (see Fig. 2a and b and 
185 S.I., Fig. S1) showed polydisperse spherical-shaped nanoparticles of 90-160 nm size. While a typical 
186 core-shell structure is observed in the TEM image in Fig. S1c, EDS mapping images (Fig. 2c-d) show 
187 the homogeneous distribution of Ca and P on the nanoshells.21 The presence of N which could only be 
188 attributed to the presence of LX is also distributed uniformly in the nanospheres (Fig. 2e), thus 
189 confirming LX inclusion in CaPLiLX nanostructure. Moreover, all electron microscopy images only 
190 show the presence of nanospheres before and after CaP coating, thus strongly supporting that no CaP 
191 separate particles are formed. 
192 The average size of 171.8 (± 0.8) nm measured by DLS for CaPLiLX suspended in aqueous 
193 suspensions is in line with the sizes observed by TEM, HR-STEM and SEM data. Therefore, a low 
194 agglomeration of CaPLiLX in aqueous suspensions may be inferred. In fact, CaPLiLX average size 
195 measured by DLS after one-week storage of the suspensions at 4 oC is of 176 (± 2) nm, thus also 
196 suggesting a good stability of CaPLiLX suspensions. 
197
198
199 Fig. 2. HR-STEM  images of CaPLiLX (a and b),  EDS elemental mapping images of Ca, P and N (c, 
200 d and e, respectively). 
























































































































202 Fig. 3 reports the ATR-FTIR spectra of LX, DOPA, CaP nanoparticles deposited in the absence of 
203 liposomes, LiLX and CaPLiLX. LiLX samples show characteristic peaks of DOPA at 1465 cm-1 and 
204 1175 cm-1 assigned to -CH2 scissoring and C-O symmetric stretching of esters in the lipid structure. 
205 Other DOPA characteristic peaks at 2695 and 1740 cm-1 are also observed in LiLX samples, as 
206 discussed further on. LiLX depict LX characteristic bands at 1625, 1250-1300 and 1085 cm-1 assigned 
207 to keto oxygen in LX ring, stretching of amines and C-F group, respectively, thus confirming the 
208 simultaneous presence of LX and DOPA liposomes in the samples.
209 After coating LiLX with a shell of calcium phosphate, the IR-ATR spectrum of CaPLiLX exhibited 
210 bands at 896, 1060 (very intense), and 1118 cm-1 characteristic of the stretching vibrations of P-OH, 
211 and P-O in phosphates. Characteristic DOPA bands at 2695, 1740, and 1465 (small) cm-1 associated 
212 to HO- vibrations of O=P-OH12 groups, stretching of ester carbonyls in lipids, and -CH2 scissoring, 
213 are also observed in CaPLiLX spectra. Bands associated to the asymmetric and symmetric stretching 
214 of carboxylate groups22 at 1577 and 1406 cm-1, respectively, may be due to attached CEPA 
215 terminations on the CaPLiLX surface. The double band at 2857-2927 cm-1 is assigned to C-H 
216 stretching confirm the presence of carbon-chains on the nanoshell surface. Interestingly, sharp peaks 
217 at 3570 cm-1 due to OH stretching in highly crystalline CaP powders,23,24 is absent in CaPLiLX 
218 spectrum. However, it should be noted  that CaP nanoparticles deposited in the absence of liposomes, 
219 but otherwise identical experimental conditions, present a spectrum coincident with that of 
220 hydroxyapatite with a distinctive sharp peak at 3570 cm-1. Therefore, suggesting that the CaP shell 
221 deposited on the liposome surface is amorphous. In line with this observation, XRD (see S.I. Fig. S2) 
222 and WAXS (see Fig. 3b) diffractograms of CaPLiLX powders and CaPLiLX aqueous suspensions, 
223 respectively, show broad and diffuse patterns characteristic of non-crystalline phases. Furthermore, no 
224 diffraction patterns were observed in HR-STEM images.24–26 
225












































































































































247 Fig. 3. (a) ATR-FTIR absorption spectra of LX (black), DOPA (red) and LiLX (green). (b) ATR-FTIR 






















































































































































249 WAXS patterns obtained from CaPLiLX colloidal suspensions in the absence (black line) and in the 
250 presence (grey line) of 0.05 M of Ca2+ ions. 
251 Two experimental conditions favored the precipitation of an amorphous CaP (ACP) shell. On one hand, 
252 the Ca/P molar ratio added to the liposomes in order to deposit the CaP shell is 1.0, without considering 
253 the lipids phosphate head groups. This ratio is in the lower limit range of 1 – 2.2 reported for 
254 amorphous phases.26 On the other hand, the presence of organic compounds (such as lipids) diminish 
255 the solubility of ions due to a change in the dielectric constant of the media.26 An increase in 
256 precipitation kinetics of Ca2+ and PO43- may occur, which favors amorphization. The amorphous phase 
257 was further stabilized by surface derivatization with CEPA.
258 3.2 Determination of liposome and encapsulated LX concentrations.
259 Liposomes encapsulation of LX, as evaluated from LX absorption at 290 nm, growths with increasing 
260 solution concentration of LX up to 100 µM. Higher LX concentrations do not lead to an increased 
261 loading of the antibiotic. A minimum LX encapsulation efficiency of 56.5% was obtained for LX 
262 solution concentrations of 100 µM, of the order reported for LX encapsulation in nanostructured 
263 myristyl myristate lipid particles employing sonication methods 27 and for that obtained in soya 
264 lecithin/cholesterol synthesized by the so-called remote loading methods.18 
265 To calculate approximately the total number of liposomes in suspension, the volume of a lipid molecule 
266 was estimated considering the approximation postulated by Koenig for unsaturated 
267 phosphatidylcholine lipids in the liquid crystalline lamellar phase. The equation 𝑉𝐿(𝑇) = 𝑉𝐻 + 𝑛𝐶𝐻𝑥
268   was used to estimate a volume of ~1300 Å3  for a DOPA 𝑉𝐶𝐻(𝑇) + 𝑛𝐶𝐻2𝑥𝑉𝐶𝐻2(𝑇) + 𝑛𝐶𝐻3𝑥𝑉𝐶𝐻3
269 molecule, where nCH, nCH2 and nCH3 are the number of carbons in double bonds, methylene-, and methyl 
270 groups respectively; and  VCH, VCH2, and VCH3 are the respective Koenig segmental volumes.28 
271 Considering that CaPLiLX size is in the range from 90 to 160 nm (as observed by TEM), that the 
272 thickness of CaP coating ranges from 20 to 40 nm 10 and the thickness of a bilayer is of ~4 nm, 29,30 a 























































































































273 simple geometrical calculation yields a bilayer volume of about 2.6107- 7.0107 Å3 for a liposome 
274 carrying the antibiotic LX. Therefore, each liposome is composed by ca. 2.0104 to 5.4104 DOPA 
275 molecules equivalent to 2.410-14- 6.510-14 mg DOPA. Since 1 mg of DOPA molecules were 
276 contained in 1 mL suspension of liposomes (see above), a concentration in suspension of 1.51013 -
277 4.21013 liposome/mL is retrieved. Considering an encapsulated LX concentration of ~3.3 µg per ml 
278 of liposome suspension after coating, then an estimate of 7.910-14- 2.210-13 µg LX/ liposome is 
279 obtained.  Therefore, the minimal bactericidal concentration (MBC) of free LX needed to treat S. 
280 aureus strains (~1.0 μg/mL) (see below) is contained in ~ 8.81012 CaP-coated liposomes, that is ca. 
281 40 % of the liposomes contained in 1 mL suspension.
282 The calcium concentration in the CaPLiLX suspension determined by ICP-OES was of 34.5 mg/kg 
283 (34.5 µg/mL). Considering that all the liposomes are covered by the CaP shell and no calcium 
284 phosphate phase is formed separately (vide supra), about 8.210-13 -2.310-12 g Ca/liposome can be 
285 estimated. Considering that the mineral phase is composed of amorphous dicalcium phosphate 
286 dyhydrate (DCP,CaHPO4.2H2O), of 2.31 gr/cm3 density31 a volume of  1.5 10 6 -4.310 7Å3  is 
287 calculated for the nanoshell from which a thickness of  ~10 nm can be estimated, in good agreement 
288 with that observed in TEM images of empty CaPLi.10
289
290 3.3 Localization of the drugs within the liposome structure.
291 LX emission spectrum obtained from CaPLiLX aqueous suspensions upon 340 nm excitation (see Fig. 
292 4a) is very broad, suggesting the localization of LX in different environments. In fact, a bilinear 
293 analysis suggests the contribution of three well differentiated emitters, denoted as E1, E2, and E3 with 
294 16, 60 and 24 % contribution to the overall emission, respectively. The emission spectra of E1 
295 (maximum emission at 430 nm) and E2 (maximum emission at 455 nm), see Fig. 4a, are in complete 
296 agreement with those obtained by TRES analysis for decay times of 1.7 ns and 6.5 ns, respectively. 
297 The E2 emission maxima and corresponding lifetime are in excellent agreement with those of LX 























































































































298 aqueous solutions of pH 7.4 showing an emission maximum (emmax) at 460 nm with decay lifetime 
299 aq of (6.2 ± 0.1) ns upon 341 nm excitation as also shown in Fig. 4a. E1 emission spectrum and decay 
300 lifetime are similar to those observed in a less polar media like hexane (hexane = (1.4 ±0.1) ns and max 
301 425 nm, see Fig. 4a), in line with the fact that hexane might resemble the low polarity environment of 
302 the DOPA bilayer. The third component, E3, with an emission maximum at 495 nm may be attributed 
303 to the protonated levofloxacin molecule, LXH+ 32 though an adsorbed specie on the CaP interface 33 
304 and binding to divalent cations 34 cannot be discarded.
305
(nm)
400 450 500 550 600
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306 Fig. 4. (a) Emission spectra of: CaPLiLX aqueous solutions upon 341 nm excitation (grey solid lines) 
307 and fitting to three components (grey dashed lines); LX aqueous solutions of pH 7.4 (black solid line) 























































































































308 and pH 4(black dashed line); LX in hexane (black dotted line); emitting specie E1 (●) and emitting 
309 specie E2 (○). (b) Time-resolved fluorescence anisotropy decay LX (exc = 341 nm) in aqueous media 
310 (●) and encapsulated in liposomes (○). The grey lines stand for the monoexponential fitting, see text.
311
312 Time resolved anisotropy experiments of LX and LiLX aqueous suspensions were performed upon 
313 341 nm excitation. The time-resolved anisotropic decays could be well fitted to a monoexponential 
314 decay for both samples as shown in Fig. 4b. The rotational correlation times obtained for LX and LiLX 
315 samples are LX=0.08 ± 0.09 ns and LiLX=1.8 ± 0.5 ns, respectively. From these values and considering 
316 spherical species, 35 hydrodynamic radius (rh) of 4.5 and 12.5 Å were estimated for LX and LiLX, 
317 respectively. While the value obtained for LX in aqueous solutions is of the order expected for small 
318 organic molecules, that obtained for LX encapsulated in the liposome suggests a motional restriction 
319 as also reported for norfloxacin in AOT reverse micelles.36
320 Altogether, the previous results support LX localization within the liposome, with a preferential 
321 location in the liposome aqueous core and minor amounts located within the lipid bilayer of the 
322 liposomes and adsorbed to the CaP shell. A similar distribution was reported for ciprofloxacin in L-
323 α-1, 2-Dipalmitoyl-sn-glycerophosphocholine liposomes.37
324
325 3.4 Drug release profiles in aqueous media as a function of pH and ions- containing media.
326 Release profiles of free LX in aqueous solution from membrane bags immersed in PBS occurs almost 
327 completely in less than 3 hours under conditions of constant stirring and ionic strength of 0.16 M and 
328 pH 7.4, as shown in Fig. 5 inset. However, in acetate buffer solution of I=0.009 M and pH 4.35, the 
329 drug was completely transferred to the media in less than one hour (see SI, Fig. S3). Thus, these 
330 observations suggest that diffusion outside the dialysis membrane may limit LX release studies from 
331 CaPLiLX for liberation times of a few hours, depending on the release media. 























































































































332 Encapsulated drug in CaPLiLX vesicles in PBS, acetate buffers and SBF media (see Fig. 5) showed a 
333 fast-initial drug release of ca. 35-45% in all the studied media during the first hours. This burst release 
334 is coincident with that observed for a sample of LX adsorbed in the outer layer of empty liposomes in 
335 PBS media.33,38,39 Since the burst release takes place in the same time window than diffusion of LX 
336 from the dialysis membrane as may be observed in Fig. 5(inset) for experiments in PBS, care should 
337 be taken in the analysis of the drug release mechanisms from these experiments.
338 To obtain some information on the mechanisms involved, the fraction of drug released at time t (RR) 
339 up to RR= 0.6 of all curves in Fig. 5 were fitted to Korsmeyer-Peppas (KP) model developed on the 
340 basis of water-soluble drug release from polymeric matrices and also applied to porous CaP-ceramic 
341 materials and composites.40,41 To that purpose, curves of RR versus time were fitted (see lines in Fig. 
342 5) to the relation , where kKP is the release rate constant which depends on the structural  𝑅𝑅 = 𝑘𝐾𝑃 × 𝑡𝑛
343 and physical characteristics of the carrier and the drug, and n is the release exponent which depends 
344 on the drug release mechanism and on the carrier geometry. The fitted parameters are displayed in SI 
345 Table S1. Obtained kKP values are, within the experimental error, similar for surface adsorbed LX in 
346 CaPLi and CaPLiLX, both, in PBS (pH 7.4) and acetate (pH 4.35) buffers, thus supporting the same 
347 nature of the vehicle in all cases. On the other hand, values of the diffusional exponent n were, within 
348 the experimental error, of ca. 0.11 for all experiments. Considering that values of n = 0.43 are reported 
349 as the limiting value for a Fickian diffusion mechanism from monodispersed spherical samples,42 the 
350 lower values of n observed here may be partly related to the size distribution polydispersity of the 
351 particles which leads to an accelerated release process at short times and a decelerated transport at long 
352 times.42 Interestingly, dialysis of free LX show kKP = 0.59 different from that of CaPLi and CaPLiLX, 
353 and n=0.6 ± 0.1 which is related to a typical diffusional mechanism. 
354 Altogether, these results further support that, any LX release form CaPLiLX vesicles in PBS and 
355 acetate buffers occurs from adsorbed LX on the CaP outer shell of the nanostructure. Such drug release 
356 occurs within the same time window of solvent free LX diffusion out of the dialysis membrane. 























































































































357 Considering that, after the first burst no further LX release is observed from CaPLiLX in PBS and 
358 acetate buffers and since liberation of surface adsorbed LX from CaPLi is complete in this time 
359 window, it may be concluded that surface adsorbed LX on the vehicle outer shell accounts for a 40 to 
360 45 % of total LX contained in CaPLiLX.
361 A different situation is observed for CaPLiLX in SBF where a preferential drug release of ca. 90% 
362 drug after 50 hs is observed, thus indicating that SBF ionic composition is responsible for the improved 
363 release. Also, kKP = 0.55 obtained in SBF (pH 7.4) similar to that of solvent free LX, seems to support 
364 an alteration in the nanocarrier facilitating the delivery of the drug. 
365  
366 Release time (h)



























367 Fig. 5. Release profiles for LX entrapped in CaPLiLX in PBS (black circles), acetate buffer solution 
368 (white triangles) and SBF (black squares). Curves stand for the fitting to Kosmeyer-Peppas model (up 
369 to ca 0.6). Inset: Release of LX adsorbed in empty CaPLi in PBS (black diamonds) and solvent free 
370 LX diffusion out of the dialysis membrane  in PBS (white diamonds). Red curves stand for the fitting 
371 to Kosmeyer-Peppas model (up to ca 0.6). Error bars stands for SD.























































































































372 3.5 Proving the release mechanism in SBF.
373 Considering the amorphous character of the CaP coating as determined by XRD experiments, we 
374 hypothesized that the presence of Ca2+ and Mg2+ ions in SBF may be involved in the improved drug 
375 release from the nanocarriers. In a first instance, the transformation of the amorphous calcium 
376 phosphate (ACP) to crystalline apatite in the presence of Ca2+ and Mg2+, in line with the reported 
377 transformation of amino acid containing amorphous calcium phosphates into apatite when immersed 
378 in calcium containing solution,43 was explored by XRD and WAXS.
379 The XRD pattern (Fig. S2) obtained for CaPLiLX deposited on a glass slide from a solution containing 
380 Ca2+ (as CaCl2 0.05 M) is coincident with that obtained in the absence of the divalent ion salt. Both 
381 samples present a broad band at 2~25ºC typical of an amorphous sample. Also, WAXS experimental 
382 patterns shown in Fig. 3b, present the same broad band in the range 20-40 º typical of amorphous 
383 samples, for both CaPLiLX, and CaPLiLX suspended in a Ca2+ solution (as CaCl2 0.05 M). Altogether, 
384 XRD and WAXS data confirm that no significant formation of a calcium phosphate crystalline phase 
385 occurs when the CaP shell gets in contact with calcium ions.
386 Formation of a coordination complex between surface carboxyl groups of nanoparticles  and Ca2+ ions 
387 is well-reported in the literature.44 Considering that our CaP nanoshells are surface-terminated by the 
388 attachment of CEPA moieties, carboxyl groups are abundant on the nanoshell surface (see ATR-FTIR 
389 results). The bonding of Ca2+ ions to these carboxyl surface groups may trigger the disassembling of 
390 the whole structure leading finally to an improved drug release. In  that sense, it was demonstrated that 
391 the presence of divalent cations as Ca2+ and Mg2+ can lead to the collapse  of  carboxylic terminated 
392 brushes of spherical colloids also provoking their aggregation.45,46 With the purpose of confirming 
393 such hypothesis, the hydrodynamic diameter and surface charge of CaPLiLX sample were evaluated 
394 in the presence of 0.05M of divalent cations (Ca2+ and Mg2+), as depicted in SI, Table S2.  An increase 
395 of the hydrodynamic diameter of the nanoshells and the consequent decrease in the electrophoretic 
396 mobility was observed in the presence of both, Ca2+ and Mg2+, supporting the formation of 























































































































397 agglomerates mediated by divalent cations-carboxyl complexes.47 Moreover, a significant increase of 
398 PDI ( 0.75) was also observed in the presence of divalent cations, which may be caused by increased 
399 nanocarrier fusion and aggregation. Considering these results and the enhanced LX release in SBF (see 
400 above), the effect of divalent cations on the agglomeration and consequent disassembling of the 
401 nanoshells in solution is strongly supported. In view of these results and bearing in mind the aim to 
402 develop a drug nanocarrier responsive to Ca2+-surfaces, we further explored the behavior of the CaP 
403 nanoshells over Ca2+- enriched surfaces by diverse microscopy studies.  
404 3.6 Interaction of nanoshell with Ca2+ rich surfaces. 
405 AFM topographic images of CaPLiLX nanoshells deposited on mica surfaces revealed spherical-like 
406 particles and some agglomerates (Fig. 6a). The height profile showed well defined spheres with an 
407 average height of 9.8 nm and an average diameter of 132.5 nm, in line with DLS, and electron 
408 microscopies results. On the other hand, images of CaPLiLX dropped on mica with the previous 
409 deposition of Ca2+ (Fig. 6b and 6c) showed the aggregation, crushing and dragging of the nanoshells 
410 on the surface. In addition, the irregular shapes registered by the probe are evident in the height profile, 
411 for both 5.0 (Fig.  6b) and 1.2 µm (Fig.  6c), where a height of ca. 4 nm is displayed, in coincidence 
412 with that observed for a phospholipid bilayer thickness.29,30 The result suggests the rupture of the CaP 
413 shell when the sample is in contact with a Ca2+ rich surface, leaving the liposomes exposed and leading 















































































































































438 Fig. 6. AFM images of CaPLiLX on mica (a) and on Ca2+ mica modified surface (b and c).
439
440 In order to explore the calcium speciation and contact time on the CaP nanoshells interaction with 
441 calcium-enriched surfaces, SEM images of CaPLiLX dropped on BGS and Ap-BGS were obtained 
442 after 10 and 120 minutes of contact (Fig. 7). Unmodified BGS scaffold’s image is also displayed (Fig. 
443 7, inset). Although nanoshells were observed on both Ap-modified and BGS unaltered surfaces, a 
444 noticeable accumulation of CaPLiLX over Ap-BGS was observed for both contact times. On the other 
445 hand, nanoshells observed in the unmodified BGS, showed uniform distribution over the surface. The 



























































































































447 on the Ap-BGS surface. The results suggest that the nanoshells have an important interaction with 



















467 Fig. 7. SEM images of (a) CaPLiLX over BGS after 10 min and (b) after 120 min. (c) CaPLiLX over 
468 Ap-BGS after 10 min and (d) after 120 min of contact time. Inset: Image of unmodified BGS scaffold.
469
470 Finally, to confirm the release of the content when the CaP nanoshells are disrupted, a new suspension 
471 of CaP coated liposomes containing acridine orange fluorophore (CaPLiAO) was prepared and 
a b
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472 observed in an epifluorescence microscope. The release of acridine orange was studied on uncoated 
473 and Ap-coated glass slides observing the morphology and changes in fluorophore emission intensity 
474 at different contact times. To that purpose, 2 mL of CaPLiAO suspension was deposited over the 
475 glasses and the whole system observed immediately (0 min) and after 10 minutes and 180 min of 
476 contact time. Control images were also obtained before adding the CaPLiAO suspension to check the 
477 absence of emission in unmodified and Ap-modified glass surfaces. The images, taken in triplicate, 
478 showed the release of the AO fluorophore from the CaP nanoshells on the Ap-modified glasses since 
479 the first minutes of contact leading to the staining of the entire Ap-modified glass surface after 180 
480 min (Fig. 8). On the other hand, the emission observed over the unmodified surface is centered in small 
481 areas corresponding to the fluorophore contained in nanoshells or their aggregates.
482
483
484 Fig.  8. Epifluorescence images of CaPLiAO interaction with Ap-modified (below) and unmodified 
485 (above) glass at 0 min, 10 min and 180 min of contact time. Control images are also displayed. Scale 
486 bar is 10 µm.
487
488 The fluorescence intensity as a function of surface and time was evaluated by calculation of the image 
489 covered area using Image J software. The results presented in Fig. S4 clearly demonstrated the 























































































































490 enhanced release of the AO fluorophore from the CaP nanoshell deposited over Ap-modified surface 
491 as observed by the naked eye.
492 Altogether, atomic force, scanning electron and epifluorescence microscopy results support the 
493 hypothesis that the CaP shells accumulate immediately after contact and break over calcium containing 
494 surfaces, exposing the liposomes, which are dissembled, releasing their drug content to the 
495 surroundings in few hours.
496
497 3.7 Time-kill curve of planktonic S. aureus. 
498 In order to confirm that the nanoshells are capable of transporting and maintaining the antibiotic 
499 activity of encapsulated LX, time-kill curve experiments were performed with LX and CaPLiLX. In 
500 vitro susceptibility of S. aureus to LX was determined on planktonic cells.  MIC and MBC (see 
501 Experimental Section) values obtained for S. aureus were 0.5 μg/mL and 1.0 μg/mL, respectively. 
502 Based in these results, LX concentration for time-kill assay was evaluated at MBC (2x MIC) value.
503 Time-kill curve for S. aureus showed that bactericidal activity was reached at 6 hours and total 
504 eradication of bacteria was achieved within 24 h for both free LX and CaPLiLX (Fig. 9). However, a 
505 difference was observed in the kinetics of the antimicrobial activity between the CaPLiLX sample and 
506 free LX. Although the antimicrobial activity is preserved for the encapsulated formulation, a small 
507 difference was observed in the first 3 hours. These results are consistent with the sustained release of 
508 LX observed from the nanoshells in solution, reaching about 40 % release in 3h in solution (~1.3 µg 
509 LX/mL) (see Fig. 5) which explains that both, CaPLiLX and LX solution, exhibited similar 
510 antimicrobial action against S. aureus. 
511












































































































































513 Fig. 9. Effects of free LX and CaPLiLX on the viability of S. aureus ATCC 25923. The in vitro time-
514 kill experiments were performed in duplicate; mean and SD values were plotted. 2x MIC LX (●) and 
515 CaPLiLX formulation().  CFU: colony forming unit.
516
517 Although the surface charge of the CaPLiLX nanoshell is negative, the nanoshells interact with the 
518 gram-positive bacterial outer membranes, leading to bacterial killing. This interaction was previously 
519 observed for acridine orange and 5,10,15,20-Tetrakis(1-methyl-4-pyridinio)porphyrin containing 
520 CaPLi nanoshells.10 The teichoic acid and the peptidoglycan components of the bacterial cell wall 
521 contribute to the negative charge of the staphylococcal cell surface. Moreover, these phosphate-
522 containing and sugar polymers are the major bacterial components for sequestering metal ions from 
523 the environment, mostly Ca2+  and Mg2+.48 In our previous work, we hinted that the phosphate groups 
524 of the bacterial cell wall and the external calcium and magnesium ions may be responsible for the 
525 preferential accumulation of the nanoshells in S. aureus biofilms and smears. As was broadly 
526 demonstrated in this work, calcium and magnesium ions also play an important role in the 
527 agglomeration and consequent disassembling of the nanoshells. We may conclude that the localization 
528 of these divalent metal ions on the vicinity of the bacterial wall may attract the nanoshells and finally 























































































































529 provoke their disruption and antibiotic content release near the bacterial cell, consistent with our 
530 proposed release mechanism.
531
532 4. CONCLUSIONS
533 Highly stable CaP-coated liposomes of 90 -160 nm size were synthesized and their capability of 
534 incorporating model drugs as the antibiotic Levofloxacin demonstrated. The drug distribution inside 
535 the aqueous core and into the bilayers was determined by steady state, time resolved and anisotropy 
536 fluorescence measurements. Drug adsorption on the CaP surface was also confirmed by release 
537 profiles. 
538 The amorphous character of the CaP shell of the vehicles is a decisive condition triggering the release 
539 of any included and surface adsorbed drug. It is well known from the literature, that amorphous CaP 
540 is more easily dissolved than crystalline calcium phosphate solids.13,49,50 The higher water content of 
541 CaP amorphous phase compared to crystalline phases may favor the entrance of the water molecules 
542 from the solvent, enhancing its dissolution. Moreover, drug release from the surface of CaP solid 
543 nanoparticles depends on the particle phase, the surface impurities, the interaction with water and the 
544 nature of the drug. The fast release observed here for adsorbed LX on the surface of CaPLiLX and 
545 CaPLi, may be due to a weak adsorption of LX on the amorphous CaP external shell. Whether such 
546 burst release is not a desired condition, the dialysis may be a good option for nanoshells purification.   
547 Because surface adsorption is involved in the drug inclusion in CaPLi vehicles, other farmaceuticals 
548 might show a different behavior, as is the case of the AO dye.10
549 The release response of CaP shells to Ca2+ and Mg2+ cations in solution showed that these divalent 
550 ions were able to complex the nanoshell surface provoking aggregation and being able to trigger the 
551 disruption of the CaP shell. In line with this behavior, an immediate response of CaP nanoshells 
552 localization to Ca2+ and hydroxyapatite-modified surfaces was observed, followed by the CaP shell 
553 disassembling and fusion of the liposome leading to the release of their content in few hours. 























































































































554 Finally, the potential of novel CaP-based nanocarriers for drug delivery applications was demonstrated 
555 in bacterial time-kill experiments of S. aureus planktonic cells as similar bacterial time-kill curves for 
556 CaPLiLX formulations and the free antibiotic were obtained probably as the consequence of the 
557 interaction of divalent cations present in the vicinity of the gram-positive bacteria with CaPLiLX.
558 Altogether, our work clearly reveals the potential of amorphous calcium organophosphate nanoshells 
559 for specific transport, localization and drug delivery to calcium-enriched surfaces, as bone tissues.
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Table of Content 
We show that amorphous calcium organophosphate nanoshells are prone to agglomerate 
and disassemble when Ca2 + ions are present in the solution and on surfaces, wich have 
great implications for targeting and controlled drug release in Ca-rich environments, such 
as bone tissues. 
 
 
Page 29 of 29 New Journal of Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
N
ew
Jo
ur
na
lo
fC
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
is
he
d 
on
 0
8 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 4
/1
5/
20
20
 3
:0
2:
06
 A
M
. 
View Article Online
DOI: 10.1039/C9NJ06414A
